The National Medical Products Administration has approved talatamab for injection, an Amgen and BeiGene-developed delta-like ligand 3/CD3 bispecific antibody, for adult patients with extensive-stage small cell lung cancer whose disease progressed after at least two prior lines of therapy including platinum-based chemotherapy, marking the first DLL3/CD3 bispecific antibody approved in China.
Amgen, a US biopharmaceutical company, and BeiGene, a China-based oncology company, jointly developed talatamab, a bispecific T-cell engager immunotherapy designed to bind delta-like ligand 3 on tumor cells and CD3 on T cells to redirect cytotoxic T-cell activity. The approval was supported by the global open-label, multicenter Phase II DeLLphi-301 trial and the China Phase II DeLLphi-307 trial. In DeLLphi-301, talatamab achieved an objective response rate of 40.0% (95% confidence interval, 31-51) and a median duration of response of 9.7 months (95% confidence interval, 2.7-20.7+). In DeLLphi-307, data cutoff March 28, 2025, 31 Chinese patients were evaluable after a median follow-up of 3.8 months; objective response rate was 39.0% (95% confidence interval, 22-58), including one complete response (3.2%) and 11 partial responses (35.5%). Median duration of response and median overall survival were not reached, while median progression-free survival was 2.9 months.
The decision expands talatamab beyond its first US approval in May 2024 and represents a regulatory milestone for DLL3-directed immunotherapy in China in relapsed or refractory extensive-stage small cell lung cancer, a setting with limited later-line treatment options. Ongoing studies are evaluating earlier-line use and maintenance or consolidation strategies, and a subcutaneous formulation remains in Phase I development.